Market Overview

UPDATE: J.P. Morgan Initiates Coverage on AbbVie with Neutral Rating, $38 PT

Related ABBV
3 Partnerships Pushing The Pharmaceutical Sector Forward
Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone
IRS, Eh? Tim Hortons Deal Could Lower Burger King's Tax Bill (Fox Business)

In a report published Wednesday, J.P. Morgan & Co. initiated coverage on AbbVie (NYSE: ABBV) with a Neutral rating and $38.00 price target.

J.P. Morgan noted, “We are initiating coverage of ABBV shares with a Neutral rating and $38 YE'13 price target. We see AbbVie as essentially a Humira story until the company is able to further diversify its business. While Humira is a well-positioned franchise and we are above the Street with our estimates over the next several years, we do not see ABBV shares getting credit for these results given the longer-term competitive threats facing the product. Rather, we believe portfolio diversification will be a key driver of multiple expansion and outperformance for the stock, and this remains several years away, in our view.”

AbbVie closed on Monday at $34.16.

Latest Ratings for ABBV

DateFirmActionFromTo
Aug 2014Credit SuisseMaintainsOutperform
Jul 2014UBSUpgradesNeutralBuy
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: J.P. Morgan & Co.Analyst Color Initiation Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters